Abstract
Patients undergoing allogeneic stem cell transplantation (allo-SCT) are given a real chance of cure, but at the same time are confronted with a considerable risk of mortality and of severe long-term impediments. This narrative, non-systematic literature review aims to describe the supportive and palliative care needs of allo-SCT recipients, including long-term survivors or those relapsing or dying after transplantation. It also evaluates the feasibility and effectivity of integrating palliative care early in transplant procedures. In this appraisal of available literature, the main findings relate to symptoms like fatigue and psychological distress, which appear to be very common in the whole allo-SCT trajectory and might even persist many years post-transplantation. Chronic GvHD has a major negative impact on quality of life. Overall, there is a paucity of research on further issues in the context of allo-SCT, like the distress related to the frequently unpredictable post-transplant trajectory and prognosis, as well as the end-of-life phase. First randomized controlled results support the effectiveness of early integration of specialized palliative care expertise into transplant algorithms. Barriers to this implementation are discussed.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
The long-term survival after allogeneic hematopoietic stem cell transplantation (allo-SCT) has been increasing, which is mostly attributable to continuous advancements in procedural aspects and supportive measures [1,2,3]. Despite these improvements, the overall mortality associated with allo-SCT remains high. The 5-year survival after allo-SCT, all diagnoses included, is about 50% [4]. Complications of the allo-SCT often lead to severe symptomatology, requiring optimal supportive and palliative management.
Palliative care aims to improve “the quality of life of patients and their families facing the problem associated with life-threatening illness, through the prevention and relief of suffering by means of early identification and impeccable assessment and treatment of pain and other problems, physical, psychosocial and spiritual” [5]. Relieving symptoms and managing other causes of suffering in cancer patients is mainly the task of oncologists and primary care teams in the sense of primary palliative care, but in complex situations, involvement of specific palliative care expertise will be necessary [6,7,8]. The early integration of such specialist palliative care into concepts of cancer therapy has become integral part of standard cancer care as recommended in several oncology and palliative care guidelines [6, 8,9,10,11]. Mounting evidence attests the effectiveness of early specialist palliative care in patients with solid tumors in the control of symptom intensity and with positive impacts on quality of life [6, 8, 9, 12, 13].
In contrast to solid cancers, specialist palliative care services are less frequently used in patients with hematological malignancies [14]. These patients receive more invasive therapies, even until shortly before death and are less likely to be informed about near death [14,15,16]. These facts from clinical practice are reflected in the current state of research in this area. There are few prospective studies that investigated the effect of early-integrated palliative care into the therapeutic algorithms in hematology [17, 18], in particular in allo-SCT [19], although recent results from randomized controlled trials indicate growing interest and research activity in that field [20,21,22].
Particularly recipients and survivors of an allo-SCT deserve special attention, because of the high morbidity and mortality associated with this modality. There is a high need to best identify and manage the many unmet needs in the field of supportive and palliative care during the whole transplant trajectory. In this non-systematic review, we aim to provide an overview on the current literature and state of the art on supportive and palliative care in patients with allo-SCT, which includes (1) symptoms, psychosocial distress, quality of life, burden related to the unpredictable illness trajectory and prognosis, issues in the last phase of life, support of family caregivers and (2) the integration of specialist palliative care services into transplant algorithms. For this purpose, we conducted a non-systematic search in the database MEDLINE (via PubMed), combining search terms on allo-SCT and on palliative care, psycho-oncology, uncertainty, fear of recurrence, or death anxiety. Further publications were identified by cross-referencing from publications listed in relevant studies and by citation tracking via the PubMed link for “related articles.” We included (systematic) reviews as well as original research articles (presented in Table 1). We considered studies including adult patients having undergone allo-SCT and/or their informal caregivers. Reviews or primary studies on hematology or SCT in general were also included if they reported specific results on allo-SCT. Primary studies with more than two-thirds of allo-SCT participants were considered as well. In this review, we also highlight relevant research gaps.
Symptoms, psychosocial distress, and quality of life
The impact of allo-SCT on symptoms and quality of life has been the topic of numerous reviews [19, 52,53,54,55,56,57,58,59,60,61,62,63,64] and more recent primary studies (see Table 1). The most prevalent physical symptoms in the first 3 months after allo-SCT are fatigue, sleep disturbances, nausea, lack of appetite, and indigestion (obstipation or diarrhea) [27, 32, 56]. Their incidences peak during the period from transplantation until 1 month thereafter [27, 32]. At about 1 month, physical symptoms start to decrease and physical functions noticeably improve [24, 32, 59] and tend to reach baseline levels at about 1 year post-transplantation [24, 59]. Overall, allo-SCT recipients after a myeloablative conditioning seem to show more symptoms and a slower recovery than those with reduced-intensity conditioning (RIC) [24, 32, 57].
Symptoms, which persist at least 1 year after allo-SCT compared with population norms and non-cancer comparison groups, include fatigue, sleeping disorders, pain, and sexual dysfunction [28, 53, 56], with fatigue being associated with female gender and younger age, as well as acute and chronic GvHD [37, 54]. In a prospective multicenter study with 239 patients, fatigue was identified as the most persistent and severe symptom even 5 years after allo-SCT; it was also the most important predictor of a reduced quality of life [38]. Even if global fatigue returned to pre-transplantation levels after about 1 year and remained stable for the next 5 years, it was still significantly more prevalent than in the general population [37].
Patients with acute graft-versus-host disease (GvHD) have a higher burden of physical symptoms and inferior physical well-being [32, 50]. Chronic GvHD is an important issue at long term and predicts very strongly the persistence of impaired physical functions [28, 54, 57].
Psychological distress is among the most prevalent symptoms in patients with allo-SCT [52,53,54]. Anxiety has been described as frequently increased especially before transplantation [40], while depression becomes prominent post-transplantation, with an increased prevalence until 10 years post-allo-SCT [40, 54]. Post-traumatic stress disorders (PTSD) is a major concern in about 5 to 19% of SCT survivors, independent of the kind of transplantation [21, 39, 54, 65]. Cognitive disorders are relatively common among patients that undergo and underwent an allo-SCT, and are frequent even before the transplantation [48, 49]. A cognitive decline from pre- to post-(allo-)SCT could not be demonstrated in a meta-analysis of 404 patients [58]. Compared to autologous SCT recipients, patients with allo-SCT appear to have a higher risk for long-term psychological distress, especially those with chronic GvHD [52, 54]. Acute and chronic GvHD both have a negative impact on mental health [50, 59].
The quality of life after transplantation has been reported to return to pre-allo-SCT levels after about 1 year [50, 54, 59]. Risk factors for poorer quality of life include young age, female gender, low educational level, limited social support, physical symptoms, and depression as well as acute and chronic GvHD [54]. Chronic GvHD is the major cause of impaired quality of life in allo-SCT survivors [55]. Patients with poorer quality of life have a higher risk of expressing regrets about their decision to undergo the allo-SCT procedure [33].
The effectiveness of early integration of specialist palliative care on symptom burden, psychological distress, and quality of life was examined in a randomized controlled trial (RCT) with 160 SCT recipients— to our knowledge the only one to date in the context of SCT [20, 21]. The interventional group received a consultation by a palliative care consultant at least twice a week during the time of hospitalization and the control group received standard transplant care. Randomization was stratified by transplant type (autologous, myeloablative allogeneic, or RIC allogeneic) with half of the patients receiving an allo-SCT. Transplant type was not found to be a mediator of the effect of the intervention. In the interventional arm, patients showed less reduction in quality of life at 2 weeks after admission, which was significant and clinically relevant (Functional Assessment of Cancer Therapy - Bone Marrow Transplantation [FACT-BMT]: mean difference between the groups −6.82 [95% CI: −13.48 to 0.16; p = 0.045]). Among secondary endpoints, at 2 weeks post-SCT, anxiety was significantly lower in the interventional group, while depression and symptom burden increased significantly less, and levels of fatigue did not differ. At 3 months post-SCT, quality of life was higher and symptoms of depression were lower in the interventional group [20]. At 6 months, the significant differences for the parameter of depression persisted and symptoms of a post-traumatic stress disorder were lower in the interventional arm [21].
Family caregivers
The impact of allo-SCT also extends to the family caregivers, who play a key role in caring for patients after discharge from the hospital [52, 64]. Most of them are spouses. They experience an increased level of anxiety and symptoms of depression as well as physical symptoms like fatigue, sleep disturbances ,weight loss, and changes in marital and social life [64]. Their own burden might also have an impact on patients’ outcomes, like mental health or number of hospitalizations [64]. More research is needed to better understand the interrelation between the needs of patients and their caregivers, and to develop targeted interventions. First results of psychological interventions are promising [66, 67]. The early integration of specialized palliative care in standard allo-SCT procedures might also positively affect caregivers’ outcomes, as shown in the mentioned RCT [20]: caregivers of patients in the intervention group had a significantly smaller increase in depression at 2 weeks as compared to caregivers of patients in the standard care arm; however, no significant differences in quality of life or anxiety were found at that time point.
Unpredictable illness trajectory and prognosis: uncertainty, fear of recurrence, and death anxiety
Allo-SCT has a high potential to provide long-term remissions of the underlying hematologic disease, but it is also associated with a high mortality [1, 2, 4]. In this context, uncertainty, death anxiety, and fear of recurrence are further sources of distress that patients experience in the context of an allo-SCT [41, 42, 46].
In allo-SCT recipients, uncertainty emerges as a main cause of burden and suffering [25, 26, 34,35,36, 43]. In a prospective cohort of 239 patients undergoing allo-SCT, uncertainty was found to be one of the predictive factors for symptoms of post-traumatic stress disorder before, 3, and 12 months after transplantation [41]. The authors hypothesized that the high uncertainty level may be due to the complex and unpredictable nature of allo-SCT, which is in line with findings on the first descriptions of patient’s uncertainty in unspecific illness situations [68,69,70]. Mishel, for instance, delineated four forms of uncertainty in a general context of illness: ambiguity regarding the state of the illness, complexity of treatment, lack of information, and unpredictability of prognosis [70]. Uncertainty in advanced illnesses like metastatic cancers has been addressed by various authors [68, 71, 72]. They confirm Mishel’s four forms of uncertainty, with complexity and unpredictability of illness being the most relevant factors at the end of life [68]. However, the exact components of uncertainty in the allo-SCT population and the ways to communicate and to manage still need to be explored [69, 73].
Fear of recurrence has been defined as the “fear, worry or concern relating to the possibility that cancer will come back or progress” [74]. Although it can be considered so far as a normal response to a cancer diagnosis, it may lead in some cases to dysfunctions like difficulties in sleeping and anxiety as well as to a decreased quality of life [75]. It therefore requires special consideration in clinical practice. The few research findings available for patients after allo-SCT indicate that about a third of them suffer from fear of recurrence [42, 45].
Fear of death is another important stress factor in allo-SCT [46]. However, it has hardly been explored to date and data from patients undergoing SCT are missing so far. A survey with 109 patients highlights fear of death as one of the main components of stress in allo-SCT, among other factors like change of life, side effects, or family concerns [46]. Prevalence rates for fear of death in patients with advanced cancer range from 30 to 80% [76, 77]. In patients treated for hematologic disease with a curative intent, preoccupation with death was found to be associated with higher anxiety and depression rates as well as with reduced coping [78]. Recently, interventions addressing death anxiety were developed (overview in [79]), but do not address allo-SCT recipients specifically.
To what extent fear of recurrence, death anxiety, and uncertainty are interrelated has been addressed rather rudimentarily [80,81,82]. Raising this issue could help to better understand distress in allo-SCT recipients and to optimize current management strategies.
End-of-life care in patients with allo-SCT
When the underlying disease fails to respond to the allo-SCT modality or side effects such as infectious complications or refractory GvHD become incurable, the patient’s condition often deteriorates quickly. The goal of care then needs to be adapted to focus on an effective symptom control and to improve the quality of life. Life-prolonging treatments (including blood transfusion) are often stopped at this point. After this change of goals of care from life-prolonging to end-of-life care, the time until death is often short [29,30,31].
The last phase of life, including the dying phase, has been investigated in some studies on patients with hematologic cancers [16, 51, 83,84,85,86]. Their findings suggest a similar symptom burden and decline in the last 3 months of life as compared to patients with solid tumors [83, 85]. For end-of-life care in patients with allo-SCT, studies are missing so far, besides two retrospective chart reviews with participants who died after allo-SCT; the patients had an elevated burden of symptoms [29, 30]. Further research is necessary to explore distress and needs of patients with allo-SCT and their informal caregivers and to describe the illness trajectory in the last phase of life.
Early integration of palliative care in the standard care of patients with allo-SCT
The early integration of specialist palliative care expertise in the transplant procedure aims at improving the experience of patients and caregivers throughout the individual trajectory, irrespective of whether that involves cure, chronic comorbidity, or death. This is achieved by improving symptom control, preventing and palliating psychosocial distress, enhancing patients’ and caregivers’ coping, and—if death nears—by caring through the last phase of life and by supporting caregivers’ bereavement [19,20,21, 87, 88]. This has been an emerging issue over the last years.
In general, the use of specialist palliative care services for patients with allo-SCT is rather infrequent, although it appears to have increased in recent years. A large retrospective US-American chart review of 21,458 patients hospitalized for SCT (40% with an allo-SCT) describes that 1.95% of allo-SCT recipients received specialized palliative care [44]. There was a significant increase in its use from 2008 to 2014 (annual percentage change 16.45%). Among the patients who died during hospitalization, the rate of involved palliative care services was only 33.40% [44].
Barriers resulting in the late and low rate of integration of specialist palliative care into the therapeutic algorithms in hematology have been described in general reviews on hematologic malignancies [14, 55, 89,90,91]. Their results are also applicable to the specific context of allo-SCT. They describe disease-related barriers like the unpredictable course of hematologic diseases or the unclear interface between a curative and palliative stage. Subjective factors play an important role as well, e.g., the perception that palliative care refers exclusively to the last phase of life, the fear to reduce patients’ hope, unrealistic expectations of patients, family members, and clinicians, or suboptimal collaborations between the disciplines of hematologists and palliative care experts [14, 55, 89,90,91].
Several models of integration of specialist palliative care in (allo)-SCT have been proposed, ranging from a selective palliative care consult ordered by the transplant team to the upfront integration of palliative care specialists in routine transplant care [19, 87]. However, such models of integration are implemented only in few institutions worldwide and thorough analyses of real-world clinical experiences are missing so far [19, 87]. Research on the efficacy of these models is also scarce. The RCT of El-Jawahri et al. mentioned previously confirmed the effectiveness of a consultative model on improving symptoms and quality of life [20, 21]. Further studies with a non-controlled prospective design supported the effectivity of other consultative models on palliative outcomes such as goals-of-care discussions, hospice referral, and keeping up hopes after talking to palliative care professionals [47, 92]. There is a need for research also on other models of integration such as co-rounding, embedded models with routine inclusion of palliative care, or models for allo-SCT survivors [19].
Discussion
Impact for clinical care
Integrating specialist palliative care early in the course of the allo-SCT procedure likely contributes to achieve the best possible symptom control, to help patients and caregivers to better cope with the illness and its prognosis (including distress by uncertainty, fear of recurrence, and death anxiety), and to optimize quality of life [17, 19, 47, 55, 87, 88]. Strategies for an early integration should be adapted to the specific issues of transplantation, as already implemented in some few projects [20, 21]. Structured interventional strategies (programs) along the whole transplant trajectory are likely to be more effective then sporadic on-demand involvements. A main issue around integrating palliative care in clinical SCT practice remains a regular contact and communication between transplant physicians and palliative care specialists in order to ensure a best possible collaboration between both disciplines. A further issue is the adequate information of patients about the advantage of integrating palliative care, even before transplantation.
Impact for research
Overall, there is a high need for further research on burden, needs, and coping of allo-SCT patients and their caregivers, regarding physical symptoms as well as psychosocial distress when facing an uncertain prognosis and death. There is also an urgent need for interventional studies evaluating the most effective strategies to integrate specialist palliative care into the allo-SCT setting. It is furthermore highly warranted to systematically assess the effect of integration of psycho-oncology, psychosocial, and supportive care services in transplant procedures on outcome parameters such as quality of life in comparison to the impact of integration of specialized palliative care.
Conclusion
During the past decades, survival of patients after allo-SCT has continually improved. Despite such better prognoses and the reduction of treatment complications, morbidity and mortality remain relatively high in this patient population. We need to better integrate palliative care into the standard care of patients with allo-SCT in order to improve symptom control, to enhance the prevention and support of psychosocial distress, and to provide best care at the end of life. Well-conducted studies around these topics are still scarce, although becoming more frequent, as far as we can judge from the results of this non-systematic review. They are urgently needed to provide best possible care and quality of life for patients undergoing an allo-SCT.
References
Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, Martin PJ, Sandmaier BM, Marr KA, Appelbaum FR, Storb R, McDonald GB (2010) Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 363(22):2091–2101. https://doi.org/10.1056/NEJMoa1004383
Majhail NS (2017) Long-term complications after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther 10(4):220–227. https://doi.org/10.1016/j.hemonc.2017.05.009
Majhail NS, Rizzo JD (2013) Surviving the cure: long term followup of hematopoietic cell transplant recipients. Bone Marrow Transplant 48(9):1145–1151. https://doi.org/10.1038/bmt.2012.258
Friedrichs B, Tichelli A, Bacigalupo A, Russell NH, Ruutu T, Shapira MY, Beksac M, Hasenclever D, Socie G, Schmitz N (2010) Long-term outcome and late effects in patients transplanted with mobilised blood or bone marrow: a randomised trial. Lancet Oncol 11(4):331–338. https://doi.org/10.1016/S1470-2045(09)70352-3
Worldwide Palliative Care Alliance/World Health Organization (2014) Global atlas of palliative care at the end of life. https://www.who.int/nmh/Global_Atlas_of_Palliative_Care.pdf. Accessed August 2020
Bausewein C, Simon ST, Pralong A, Radbruch L, Nauck F, Voltz R (2015) Palliative care of adult patients with cancer. Dtsch Arztebl Int 112(50):863–870. https://doi.org/10.3238/arztebl.2015.0863
Radbruch L, Payne S (2009) White Paper on standards and norms for hospice and palliative care in Europe: part 1. Eur J Palliat Care 16(6):278–289
Simon ST, Pralong A, Radbruch L, Bausewein C, Voltz R (2020) The palliative care of patients with incurable cancer. Dtsch Arztebl Int 116(7):108–115. https://doi.org/10.3238/arztebl.2020.0108
Ferrell BR, Temel JS, Temin S, Alesi ER, Balboni TA, Basch EM, Firn JI, Paice JA, Peppercorn JM, Phillips T, Stovall EL, Zimmermann C, Smith TJ (2017) Integration of palliative care into standard oncology care: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 35(1):96–112
National Coalition for Hospice and Palliative Care (2018) Clinical practice guidelines for quality palliative care, 4th edition. https://www.nationalcoalitionhpc.org/wp-content/uploads/2018/10/NCHPC-NCPGuidelines_4thED_web_FINAL.pdf. Accessed September 2020
National Comprehensive Cancer Network (NCCN) (2020) Palliative care, Version 1.2020. https://www.nccn.org/guidelines/guidelines-detail?category=3&id=1454. Accessed August 2020
Gaertner J, Siemens W, Meerpohl JJ, Antes G, Meffert C, Xander C, Stock S, Mueller D, Schwarzer G, Becker G (2017) Effect of specialist palliative care services on quality of life in adults with advanced incurable illness in hospital, hospice, or community settings: systematic review and meta-analysis. BMJ 357:j2925. https://doi.org/10.1136/bmj.j2925
Haun MW, Estel S, Rucker G, Friederich HC, Villalobos M, Thomas M, Hartmann M (2017) Early palliative care for adults with advanced cancer. Cochrane Database Syst Rev 6:CD011129. https://doi.org/10.1002/14651858.CD011129.pub2
Howell DA, Shellens R, Roman E, Garry AC, Patmore R, Howard MR (2011) Haematological malignancy: are patients appropriately referred for specialist palliative and hospice care? A systematic review and meta-analysis of published data. Palliat Med 25(6):630–641. https://doi.org/10.1177/0269216310391692
Beaussant Y, Daguindau E, Chauchet A, Rochigneux P, Tournigand C, Aubry R, Morin L (2018) Hospital end-of-life care in haematological malignancies. BMJ Support Palliat Care 8(3):314–324. https://doi.org/10.1136/bmjspcare-2017-001446
Eichenauer DA, Golla H, Thielen I, Hallek M, Voltz R, Perrar KM (2019) Characteristics and course of patients with advanced hematologic malignancies receiving specialized inpatient palliative care at a German university hospital. Ann Hematol 98:2605–2607. https://doi.org/10.1007/s00277-019-03748-1
LeBlanc TW, El-Jawahri A (2018) Hemato-oncology and palliative care teams: is it time for an integrated approach to patient care? Curr Opin Support Palliat Care 12(4):530–537. https://doi.org/10.1097/SPC.0000000000000385
Oechsle K (2019) Palliative care in patients with hematological malignancies. Oncol Res Treat 42(1-2):25–30. https://doi.org/10.1159/000495424
Mitchell SA (2018) Palliative care during and following allogeneic hematopoietic stem cell transplantation. Curr Opin Support Palliat Care 12(1):58–64. https://doi.org/10.1097/SPC.0000000000000327
El-Jawahri A, LeBlanc T, VanDusen H, Traeger L, Greer JA, Pirl WF, Jackson VA, Telles J, Rhodes A, Spitzer TR, McAfee S, Chen YA, Lee SS, Temel JS (2016) Effect of inpatient palliative care on quality of life 2 weeks after hematopoietic stem cell transplantation: a randomized clinical trial. JAMA 316(20):2094–2103. https://doi.org/10.1001/jama.2016.16786
El-Jawahri A, Traeger L, Greer JA, VanDusen H, Fishman SR, LeBlanc TW, Pirl WF, Jackson VA, Telles J, Rhodes A, Li Z, Spitzer TR, McAfee S, Chen YA, Temel JS (2017) Effect of inpatient palliative care during hematopoietic stem-cell transplant on psychological distress 6 months after transplant: results of a randomized clinical trial. J Clin Oncol 35(32):3714–3721. https://doi.org/10.1200/JCO.2017.73.2800
El-Jawahri A, LeBlanc TW, Kavanaugh A, Webb J, Jackson VA, Campbell TC, O’Connor N, Luger SM, Gafford E, Gustin J, Bhatnagar B, Fathi AT, Hobbs G, Foster J, Nicholson S, Davis DM, Addis H, Vaughn D, Horick NK, Temel JS (2020) Multisite randomized trial of integrated palliative and oncology care for patients with acute myeloid leukemia (AML). J Clin Oncol 38(15_suppl):12000. https://doi.org/10.1200/JCO.2020.38.15_suppl.12000
Amonoo HL, Brown LA, Scheu CF, Millstein RA, Pirl WF, Vitagliano HL, Antin JH, Huffman JC (2019) Positive psychological experiences in allogeneic hematopoietic stem cell transplantation. Psychooncology 28(8):1633–1639. https://doi.org/10.1002/pon.5128
Andersson I, Ahlberg K, Stockelberg D, Persson LO (2011) Patients’ perception of health-related quality of life during the first year after autologous and allogeneic stem cell transplantation. Eur J Cancer Care (Engl) 20(3):368–379. https://doi.org/10.1111/j.1365-2354.2009.01174.x
Bergkvist K, Larsen J, Johansson UB, Mattsson J, Fossum B (2018) Family members’ life situation and experiences of different caring organisations during allogeneic haematopoietic stem cells transplantation-a qualitative study. Eur J Cancer Care (Engl) 27(1). https://doi.org/10.1111/ecc.12610
Bergkvist K, Winterling J, Kisch AM (2020) Support in the context of allogeneic hematopoietic stem cell transplantation - the perspectives of family caregivers. Eur J Oncol Nurs 46:101740. https://doi.org/10.1016/j.ejon.2020.101740
Bevans MF, Mitchell SA, Marden S (2008) The symptom experience in the first 100 days following allogeneic hematopoietic stem cell transplantation (HSCT). Support Care Cancer 16(11):1243–1254. https://doi.org/10.1007/s00520-008-0420-6
Bevans MF, Mitchell SA, Barrett JA, Bishop MR, Childs R, Fowler D, Krumlauf M, Prince P, Shelburne N, Wehrlen L, Yang L (2014) Symptom distress predicts long-term health and well-being in allogeneic stem cell transplantation survivors. Biol Blood Marrow Transplant 20(3):387–395. https://doi.org/10.1016/j.bbmt.2013.12.001
Busemann C, Julich A, Buchhold B, Schmidt V, Schneidewind L, Pink D, Schmidt CA, Neumann T, Kruger WH (2017) Clinical course and end-of-life care in patients who have died after allogeneic stem cell transplantation. J Cancer Res Clin Oncol 143(10):2067–2076. https://doi.org/10.1007/s00432-017-2446-y
Button EB, Gavin NC, Keogh SJ (2014) Exploring palliative care provision for recipients of allogeneic hematopoietic stem cell transplantation who relapsed. Oncol Nurs Forum 41(4):370–381. https://doi.org/10.1188/14.ONF.370-381
Cappell K, Sundaram V, Park A, Shiraz P, Gupta R, Jenkins P, Periyakoil VSJ, Muffly L (2018) Advance directive utilization is associated with less aggressive e-of-life care in patients undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 24(5):1035–1040. https://doi.org/10.1016/j.bbmt.2018.01.014
Cohen MZ, Rozmus CL, Mendoza TR, Padhye NS, Neumann J, Gning I, Aleman A, Giralt S, Cleeland CS (2012) Symptoms and quality of life in diverse patients undergoing hematopoietic stem cell transplantation. J Pain Symptom Manag 44(2):168–180. https://doi.org/10.1016/j.jpainsymman.2011.08.011
Cusatis RN, Tecca HR, D’Souza A, Shaw BE, Flynn KE (2020) Prevalence of decisional regret among patients who underwent allogeneic hematopoietic stem cell transplantation and associations with quality of life and clinical outcomes. Cancer 126(11):2679–2686. https://doi.org/10.1002/cncr.32808
Dunn E, Arber A, Gallagher A (2016) The immediacy of illness and existential crisis: patients’ lived experience of under-going allogeneic stem cell transplantation for haematological malignancy. A phenomenological study. Eur J Oncol Nurs 21:90–96. https://doi.org/10.1016/j.ejon.2016.01.001
El-Jawahri A, Traeger L, Kuzmuk K, Eusebio J, Vandusen H, Keenan T, Shin J, Gallagher ER, Greer JA, Pirl WF, Jackson VA, Ballen KK, Spitzer TR, Graubert TA, McAfee S, Dey B, Chen YB, Temel JS (2015) Prognostic understanding, quality of life and mood in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 50(8):1119–1124. https://doi.org/10.1038/bmt.2015.113
El-Jawahri AR, Traeger LN, Kuzmuk K, Eusebio JR, Vandusen HB, Shin JA, Keenan T, Gallagher ER, Greer JA, Pirl WF, Jackson VA, Ballen KK, Spitzer TR, Graubert TA, McAfee SL, Dey BR, Chen YB, Temel JS (2015) Quality of life and mood of patients and family caregivers during hospitalization for hematopoietic stem cell transplantation. Cancer 121(6):951–959. https://doi.org/10.1002/cncr.29149
Esser P, Kuba K, Mehnert A, Schwinn A, Schirmer L, Schulz-Kindermann F, Kruse M, Koch U, Zander AR, Kroger N, Schilling G, Gotze H, Scherwath A (2017) Investigating the temporal course, relevance and risk factors of fatigue over 5 years: a prospective study among patients receiving allogeneic HSCT. Bone Marrow Transplant 52(5):753–758. https://doi.org/10.1038/bmt.2016.344
Esser P, Kuba K, Scherwath A, Johansen C, Schwinn A, Schirmer L, Schulz-Kindermann F, Kruse M, Koch U, Zander AR, Kroger N, Gotze H, Mehnert A (2017) Stability and priority of symptoms and symptom clusters among allogeneic HSCT patients within a 5-year longitudinal study. J Pain Symptom Manag 54(4):493–500. https://doi.org/10.1016/j.jpainsymman.2017.07.012
Esser P, Kuba K, Scherwath A, Schirmer L, Schulz-Kindermann F, Dinkel A, Balck F, Koch U, Kroger N, Gotze H, Mehnert A (2017) Posttraumatic stress disorder symptomatology in the course of allogeneic HSCT: a prospective study. J Cancer Surviv 11(2):203–210. https://doi.org/10.1007/s11764-016-0579-7
Kuba K, Esser P, Mehnert A, Johansen C, Schwinn A, Schirmer L, Schulz-Kindermann F, Kruse M, Koch U, Zander A, Kroger N, Gotze H, Scherwath A (2017) Depression and anxiety following hematopoietic stem cell transplantation: a prospective population-based study in Germany. Bone Marrow Transplant 52(12):1651–1657. https://doi.org/10.1038/bmt.2017.190
Kuba K, Esser P, Scherwath A, Schirmer L, Schulz-Kindermann F, Dinkel A, Balck F, Koch U, Kroger N, Gotze H, Mehnert A (2017) Cancer-and-treatment-specific distress and its impact on posttraumatic stress in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Psychooncology 26(8):1164–1171. https://doi.org/10.1002/pon.4295
Sarkar S, Scherwath A, Schirmer L, Schulz-Kindermann F, Neumann K, Kruse M, Dinkel A, Kunze S, Balck F, Kroger N, Koch U, Mehnert A (2014) Fear of recurrence and its impact on quality of life in patients with hematological cancers in the course of allogeneic hematopoietic SCT. Bone Marrow Transplant 49(9):1217–1222. https://doi.org/10.1038/bmt.2014.139
Grulke N, Bunjes D, Larbig W, Kachele H, Bailer H (2008) Physicians’ prognostic estimates of survival for patients undergoing allogeneic hematopoietic stem cell transplantation. J Psychosom Res 65(1):61–66. https://doi.org/10.1016/j.jpsychores.2008.01.008
Han H, Liu Y, Qin Y, Guo W, Ruan Y, Wu C, Cao Y, He J (2019) Utilization of palliative care for patients undergoing hematopoietic stem cell transplantation during hospitalization: a population-based national study. Am J Hosp Palliat Care 36(10):900–906. https://doi.org/10.1177/1049909119838975
Hefner J, Kapp M, Drebinger K, Dannenmann A, Einsele H, Grigoleit GU, Faller H, Csef H, Mielke S (2014) High prevalence of distress in patients after allogeneic hematopoietic SCT: fear of progression is associated with a younger age. Bone Marrow Transplant 49(4):581–584. https://doi.org/10.1038/bmt.2013.228
Heinonen H, Volin L, Zevon MA, Uutela A, Barrick C, Ruutu T (2005) Stress among allogeneic bone marrow transplantation patients. Patient Educ Couns 56(1):62–71. https://doi.org/10.1016/j.pec.2003.12.007
Loggers ET, LeBlanc TW, El-Jawahri A, Fihn J, Bumpus M, David J, Horak P, Lee SJ (2016) Pretransplantation supportive and palliative care consultation for high-risk hematopoietic cell transplantation patients. Biol Blood Marrow Transplant 22(7):1299–1305. https://doi.org/10.1016/j.bbmt.2016.03.006
Scherwath A, Schirmer L, Kruse M, Ernst G, Eder M, Dinkel A, Kunze S, Balck F, Bornhauser M, Ehninger G, Dolan K, Gramatzki M, Kolb HJ, Heussner P, Wilhelm H, Beelen DW, Schulz-Kindermann F, Zander AR, Koch U, Mehnert A (2013) Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study. Psychooncology 22(7):1509–1516. https://doi.org/10.1002/pon.3159
Schulz-Kindermann F, Mehnert A, Scherwath A, Schirmer L, Schleimer B, Zander AR, Koch U (2007) Cognitive function in the acute course of allogeneic hematopoietic stem cell transplantation for hematological malignancies. Bone Marrow Transplant 39(12):789–799. https://doi.org/10.1038/sj.bmt.1705663
Valkova V, Jircikova J, Trnkova M, Steinerova K, Keslova P, Lanska M, Koristek Z, Raida L, Krejci M, Kruntoradova K, Dolezal T, Benesova K, Cetkovsky P, Trneny M (2016) The quality of life following allogeneic hematopoietic stem cell transplantation - a multicenter retrospective study. Neoplasma 63(5):743–751. https://doi.org/10.4149/neo_2016_511
Wang WS, Ma JD, Nelson SH, Revta C, Buckholz GT, Mulroney CM, Roeland EJ (2017) Advance care planning and palliative care integration for patients undergoing hematopoietic stem-cell transplantation. J Oncol Pract 13(9):e721–e728. https://doi.org/10.1200/JOP.2016.020321
Amonoo HL, Massey CN, Freedman ME, El-Jawahri A, Vitagliano HL, Pirl WF, Huffman JC (2019) Psychological considerations in hematopoietic stem cell transplantation. Psychosomatics 60(4):331–342. https://doi.org/10.1016/j.psym.2019.02.004
Bevans M (2010) Health-related quality of life following allogeneic hematopoietic stem cell transplantation. Hematology Am Soc Hematol Educ Program 2010:248–254. https://doi.org/10.1182/asheducation-2010.1.248
Bevans M, El-Jawahri A, Tierney DK, Wiener L, Wood WA, Hoodin F, Kent EE, Jacobsen PB, Lee SJ, Hsieh MM, Denzen EM, Syrjala KL (2017) National Institutes of Health hematopoietic cell transplantation late effects initiative: the patient-centered outcomes working group report. Biol Blood Marrow Transplant 23(4):538–551. https://doi.org/10.1016/j.bbmt.2016.09.011
El-Jawahri A, Nelson AM, Gray TF, Lee SJ, LeBlanc TW (2020) Palliative and end-of-life care for patients with hematologic malignancies. J Clin Oncol 38(9):944–953. https://doi.org/10.1200/JCO.18.02386
Jim HS, Evans B, Jeong JM, Gonzalez BD, Johnston L, Nelson AM, Kesler S, Phillips KM, Barata A, Pidala J, Palesh O (2014) Sleep disruption in hematopoietic cell transplantation recipients: prevalence, severity, and clinical management. Biol Blood Marrow Transplant 20(10):1465–1484. https://doi.org/10.1016/j.bbmt.2014.04.010
Mohty B, Mohty M (2011) Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update. Blood Cancer J 1(4):e16. https://doi.org/10.1038/bcj.2011.14
Phillips KM, McGinty HL, Cessna J, Asvat Y, Gonzalez B, Cases MG, Small BJ, Jacobsen PB, Pidala J, Jim HS (2013) A systematic review and meta-analysis of changes in cognitive functioning in adults undergoing hematopoietic cell transplantation. Bone Marrow Transplant 48(10):1350–1357. https://doi.org/10.1038/bmt.2013.61
Pidala J, Anasetti C, Jim H (2009) Quality of life after allogeneic hematopoietic cell transplantation. Blood 114(1):7–19. https://doi.org/10.1182/blood-2008-10-182592
Pidala J, Anasetti C, Jim H (2010) Health-related quality of life following haematopoietic cell transplantation: patient education, evaluation and intervention. Br J Haematol 148(3):373–385. https://doi.org/10.1111/j.1365-2141.2009.07992.x
Pidala J (2011) Graft-vs-host disease following allogeneic hematopoietic cell transplantation. Cancer Control 18(4):268–276. https://doi.org/10.1177/107327481101800407
Roeland E, Mitchell W, Elia G, Thornberry K, Herman H, Cain J, Atayee R, Bardwell W, von Gunten CF (2010) Symptom control in stem cell transplantation: a multidisciplinary palliative care team approach. Part 2: psychosocial concerns. J Support Oncol 8(4):179–183
Roeland E, Mitchell W, Elia G, Thornberry K, Herman H, Cain J, Atayee R, Bardwell W, von Gunten CF (2010) Symptom control in stem cell transplantation: a multidisciplinary palliative care team approach. Part 1: Physical symptoms. J Support Oncol 8(3):100–116
Wulff-Burchfield EM, Jagasia M, Savani BN (2013) Long-term follow-up of informal caregivers after allo-SCT: a systematic review. Bone Marrow Transplant 48(4):469–473. https://doi.org/10.1038/bmt.2012.123
Mosher CE, Redd WH, Rini CM, Burkhalter JE, DuHamel KN (2009) Physical, psychological, and social sequelae following hematopoietic stem cell transplantation: a review of the literature. Psychooncology 18(2):113–127. https://doi.org/10.1002/pon.1399
Laudenslager ML, Simoneau TL, Mikulich-Gilbertson SK, Natvig C, Brewer BW, Sannes TS, Kilbourn K, Gutman J, McSweeney P (2019) A randomized control trial of stress management for caregivers of stem cell transplant patients: effect on patient quality of life and caregiver distress. Psychooncology 28(8):1614–1623. https://doi.org/10.1002/pon.5126
Vinci C, Pidala J, Lau P, Reblin M, Jim H (2020) A mindfulness-based intervention for caregivers of allogeneic hematopoietic stem cell transplant patients: Pilot results. Psychooncology 29(5):934–937. https://doi.org/10.1002/pon.5353
Etkind SN, Bristowe K, Bailey K, Selman LE, Murtagh FE (2017) How does uncertainty shape patient experience in advanced illness? A secondary analysis of qualitative data. Palliat Med 31(2):171–180. https://doi.org/10.1177/0269216316647610
Hansen BS, Rortveit K, Leiknes I, Morken I, Testad I, Joa I, Severinsson E (2012) Patient experiences of uncertainty - a synthesis to guide nursing practice and research. J Nurs Manag 20(2):266–277. https://doi.org/10.1111/j.1365-2834.2011.01369.x
Mishel MH (1988) Uncertainty in illness. Image J Nurs Sch 20(4):225–232. https://doi.org/10.1111/j.1547-5069.1988.tb00082.x
Kimbell B, Boyd K, Kendall M, Iredale J, Murray SA (2015) Managing uncertainty in advanced liver disease: a qualitative, multiperspective, serial interview study. BMJ Open 5(11):e009241. https://doi.org/10.1136/bmjopen-2015-009241
Nanton V, Munday D, Dale J, Mason B, Kendall M, Murray S (2016) The threatened self: considerations of time, place, and uncertainty in advanced illness. Br J Health Psychol 21(2):351–373. https://doi.org/10.1111/bjhp.12172
Politi MC, Han PK, Col NF (2007) Communicating the uncertainty of harms and benefits of medical interventions. Med Decis Mak 27(5):681–695. https://doi.org/10.1177/0272989X07307270
Lebel S, Ozakinci G, Humphris G, Mutsaers B, Thewes B, Prins J, Dinkel A, Butow P, University of Ottawa Fear of Cancer Recurrence Colloquium a (2016) From normal response to clinical problem: definition and clinical features of fear of cancer recurrence. Support Care Cancer 24(8):3265–3268. https://doi.org/10.1007/s00520-016-3272-5
Mehnert A, Koch U, Sundermann C, Dinkel A (2013) Predictors of fear of recurrence in patients one year after cancer rehabilitation: a prospective study. Acta Oncol 52(6):1102–1109. https://doi.org/10.3109/0284186X.2013.765063
Cherny NI, Coyle N, Foley KM (1994) Suffering in the advanced cancer patient: a definition and taxonomy. J Palliat Care 10(2):57–70
Neel C, Lo C, Rydall A, Hales S, Rodin G (2015) Determinants of death anxiety in patients with advanced cancer. BMJ Support Palliat Care 5(4):373–380. https://doi.org/10.1136/bmjspcare-2012-000420
Vollmer TC, Wittmann M, Schweiger C, Hiddemann W (2011) Preoccupation with death as predictor of psychological distress in patients with haematologic malignancies. Eur J Cancer Care (Engl) 20(3):403–411. https://doi.org/10.1111/j.1365-2354.2010.01203.x
Grossman CH, Brooker J, Michael N, Kissane D (2018) Death anxiety interventions in patients with advanced cancer: A systematic review. Palliat Med 32(1):172–184. https://doi.org/10.1177/0269216317722123
Curran L, Sharpe L, MacCann C, Butow P (2020) Testing a model of fear of cancer recurrence or progression: the central role of intrusions, death anxiety and threat appraisal. J Behav Med 43(2):225–236. https://doi.org/10.1007/s10865-019-00129-x
Lebel S, Maheu C, Lefebvre M, Secord S, Courbasson C, Singh M, Jolicoeur L, Benea A, Harris C, Fung MF, Rosberger Z, Catton P (2014) Addressing fear of cancer recurrence among women with cancer: a feasibility and preliminary outcome study. J Cancer Surviv 8(3):485–496. https://doi.org/10.1007/s11764-014-0357-3
Sharpe L, Curran L, Butow P, Thewes B (2018) Fear of cancer recurrence and death anxiety. Psychooncology 27(11):2559–2565. https://doi.org/10.1002/pon.4783
Fadul NA, El Osta B, Dalal S, Poulter VA, Bruera E (2008) Comparison of symptom burden among patients referred to palliative care with hematologic malignancies versus those with solid tumors. J Palliat Med 11(3):422–427. https://doi.org/10.1089/jpm.2007.0184
Kaiser F, Rudloff LV, Vehling-Kaiser U, Hollburg W, Nauck F, Alt-Epping B (2017) Palliative home care for patients with advanced haematological malignancies-a multicenter survey. Ann Hematol 96(9):1557–1562. https://doi.org/10.1007/s00277-017-3045-3
LeBlanc TW, Smith JM, Currow DC (2015) Symptom burden of haematological malignancies as death approaches in a community palliative care service: a retrospective cohort study of a consecutive case series. Lancet Haematol 2(8):e334–e338. https://doi.org/10.1016/S2352-3026(15)00111-8
McCaughan D, Roman E, Smith AG, Garry AC, Johnson MJ, Patmore RD, Howard MR, Howell DA (2019) Perspectives of bereaved relatives of patients with haematological malignancies concerning preferred place of care and death: a qualitative study. Palliat Med 33(5):518–530. https://doi.org/10.1177/0269216318824525
Levine DR, Baker JN, Wolfe J, Lehmann LE, Ullrich C (2017) Strange bedfellows no more: how integrated stem-cell transplantation and palliative care programs can together improve end-of-life care. J Oncol Pract 13(9):569–577. https://doi.org/10.1200/JOP.2017.021451
Tierney DK, Passaglia J, Jenkins P (2014) Palliative care of hematopoietic cell transplant recipients and families. Semin Oncol Nurs 30(4):253–261. https://doi.org/10.1016/j.soncn.2014.08.007
El-Jawahri A, LeBlanc TW, Burns LJ, Denzen E, Meyer C, Mau LW, Roeland EJ, Wood WA, Petersdorf E (2018) What do transplant physicians think about palliative care? A national survey study. Cancer 124(23):4556–4566. https://doi.org/10.1002/cncr.31709
LeBlanc TW, El-Jawahri A (2015) When and why should patients with hematologic malignancies see a palliative care specialist? Hematology Am Soc Hematol Educ Program 2015:471–478. https://doi.org/10.1182/asheducation-2015.1.471
Moreno-Alonso D, Porta-Sales J, Monforte-Royo C, Trelis-Navarro J, Sureda-Balari A, Fernandez De Sevilla-Ribosa A (2018) Palliative care in patients with haematological neoplasms: an integrative systematic review. Palliat Med 32(1):79–105. https://doi.org/10.1177/0269216317735246
Selvaggi KJ, Vick JB, Jessell SA, Lister J, Abrahm JL, Bernacki R (2014) Bridging the gap: a palliative care consultation service in a hematological malignancy-bone marrow transplant unit. J Commun Support Oncol 12(2):50–55. https://doi.org/10.12788/jcso.0015
Code availability
Not applicable.
Funding
Open Access funding enabled and organized by Projekt DEAL.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Simon, S.T., Pralong, A., Hallek, M. et al. What is known about palliative care in adult patients with allogeneic stem cell transplantation (allo-SCT)?. Ann Hematol 100, 1377–1389 (2021). https://doi.org/10.1007/s00277-021-04538-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-021-04538-4